Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Tokio Marine Eyes Multibillion-Dollar Suncorp Takeover 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Ampol Profit Surges as Refining Margins Hit Record Highs 
Tesla Raises Cybertruck Prices by $5,000 in US 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Trump Buys SpaceX Shares After Record IPO 
SK Hynix Shares Fall as Workers Reject Wage Deal 
Luxshare Shares Rise as First-Half Profit Jumps 18% 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
Woodside Drops $5 Billion Clean Energy Plan as Profit Rises 7% 
Nvidia Options Price in $280 Billion Earnings Swing 
Samsung Shares Tumble 8% as $79 Billion Return Plan Disappoints 
Add as a preferred source on Google
NOVATO, Calif., May 01, 2018 -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today announced that it will host a conference call on Monday, May 7, 2018 at 5pm ET to discuss first quarter 2018 financial results and provide a corporate update.
The live and replayed webcast of the call will be available through the company’s website at http://ir.ultragenyx.com/events.cfm. To participate in the live call by phone, dial 855-797-6910 (USA) or 262-912-6260 (international) and enter the passcode 3748439. The replay of the call will be available for one year.
About Ultragenyx
Ultragenyx is a biopharmaceutical company committed to bringing to patients novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has rapidly built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company’s website at www.ultragenyx.com.
Contact Ultragenyx Pharmaceutical Inc.
Investors & Media
Danielle Keatley
415-475-6876
